Fresh analysis indicates that patients who come off new GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who halt conventional diet and exercise plans.
Findings released in a major medical journal points out that while overweight individuals can lose about a fifth of their body weight while undergoing treatment, the weight returns at an estimated rate of 0.8 kg per month after stopping.
"Users purchasing these treatments must be cognizant of the risk of quick rebound weight gain when the medication concludes," cautioned researcher Dr. Susan Jebb.
That rate of recovery implies a reversion to pre-treatment weight in about one and a half years.
Weighing Treatments
The analysis, which reviewed 37 of studies involving thousands of participants, compared the effects of these new drugs with other pills.
The team note that individuals who lose weight through lifestyle changes alone typically see a less rapid weight regain—approximately 100 grams monthly—once they finish.
Explaining the Fast Regain
Nutrition scientists propose the mechanism of the injections is key to understanding the heightened rebound.
The injections copy a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Long-term administration of GLP-1 concentrations several times higher than the body's typical production might result in the system to produce less of its own natural hormone, and may also diminish responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this GLP-1 'fix' leads to appetite is uncontrolled, making overeating far more likely."
A Lifelong Issue?
Health authorities advise the injections for people with weight-linked health risks, alongside prescribed diet and exercise modifications.
A number of clinicians say that, considering the significant potential of weight regain, the therapy might need to be ongoing.
This perspective is echoed by drug manufacturers, who note that the findings "highlight the persistent character of obesity," comparing it to managing conditions like diabetes.
User Experiences
Users who have discontinued the medication report a sudden return of appetite.
"It felt as if a switch activating and you're instantly ravenous," described an individual.
This challenge is compounded if individuals have not adopted lasting dietary or behavioural modifications during therapy.
Growing Interest
Recent estimates show that millions of people in the UK have tried weight-loss jabs in the last 12 months, with desire remaining high.
- Adoption is higher among women than males.
- The middle-aged demographic shows the highest level of interest.
- Many obtain the medications through private healthcare rather than the NHS.
In conclusion, clinicians emphasize that while the jabs are effective agents for shedding pounds, they are not a standalone solution and maintained weight loss likely depends on integrated behavioural changes.
